MARK HIGGINS: Open Payments
NPI 1134193469 · SAN FRANCISCO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,181 in 190 payments from 28 companies in 2025. Trend: 2023 $4,495 · 2024 $6,034 · 2025 $4,181
Food & beverage: $4,181
| Company | Payments | Amount |
|---|---|---|
| ViiV Healthcare Company | 41 | $692 |
| Gilead Sciences, Inc. | 23 | $631 |
| ABBVIE INC. | 21 | $413 |
| EMD Serono, Inc. | 23 | $385 |
| AstraZeneca Pharmaceuticals LP | 15 | $357 |
| PFIZER INC. | 14 | $306 |
| Merck Sharp & Dohme LLC | 7 | $196 |
| Novo Nordisk Inc | 11 | $194 |
| Axsome Therapeutics, Inc. | 1 | $138 |
| Boston Scientific Corporation | 1 | $102 |
Products named: CABENUVA, AIRSUPRA, DOVATO, RUKOBIA, ELIQUIS, VIBERZI, Auvelity, VRAYLAR.
Industry payments across CA — which companies pay providers there.
